HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 290/6/G1157    most recent 00544.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (40) Citing Articles via Google Scholar Google Scholar Articles by Gewirtz, A. T. Articles by Cho, J. H. Search for Related Content PubMed PubMed Citation Articles by Gewirtz, A. T. Articles by Cho, J. H.

INFLAMMATION/IMMUNITY/MEDIATORS

Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease

¹Department of Pathology and Laboratory Medicine, Epithelial Pathobiology Unit, Emory University School of Medicine, Atlanta, Georgia; ²Departments of Medicine, and Statistics, The University of Chicago, Chicago, Illinois; ⁴Department of Medicine, Johns Hopkins School of Medicine Baltimore, Maryland; and ³Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

Submitted 29 November 2005 ; accepted in final form 24 January 2006

Crohn's disease (CD) is associated with elevated adaptive immunity to commensal microbes, with flagellin being a dominant antigen. In light of heightened awareness of the importance of innate immunity in regulating adaptive immunity and ambiguity as to the role of CD-associated immune responses in CD pathophysiology, we sought to determine whether natural acquisition of immune responses to flagellin were regulated by the innate immune flagellin receptor toll-like receptor 5 (TLR5) and determine whether persons carrying a recently defined common dominant-negative TLR5 polymorphism (TLR5-stop) might be protected from developing CD. Carriage rates of a recently defined dominant-negative TLR5 polymorphism (TLR5-stop) and levels of serum immunoreactivity to bacterial products were measured in inflammatory bowel disease patients, first-degree relatives, and unrelated controls. We observed that, in healthy subjects, persons carrying TLR5-stop had significantly lower levels of flagellin-specific IgG and IgA but had similar levels of total and LPS-specific Ig. Moreover, we observed that, among Jewish subjects, the carriage rate of TLR5-stop (in heterozygous state) was significantly less in CD patients, but not ulcerative colitis (UC) patients, compared with unaffected relatives and unrelated controls (5.4, 0.9, 6.0, and 6.5% for unaffected relatives, CD, UC, and unrelated Jewish controls, respectively, n = 296, 215, 185, and 416, respectively; P = 0.037 by likelihood calculation for CD vs. controls), indicating that TLR5-stop can protect persons of Jewish ethnicity against CD. We did not observe a significant association of TLR5-stop with CD in a non-Jewish cohort (11.1, 10.4, and 11.7% for unaffected relatives, CD, and UC, respectively; n = 841, 543, and 300 for unaffected relatives, respectively). These results demonstrate that natural acquisition of immune responses to flagellin are regulated by TLR5 and suggest that immune responses to flagellin are not merely associated with CD but rather promote the pathogenic response.

inflammatory bowel disease; lipopolysacharride; serum immunoglobulins

This article has been cited by other articles:

				L. A. J. O'Neill, C. E. Bryant, and S. L. Doyle Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer Pharmacol. Rev., June 1, 2009; 61(2): 177 - 197. [Abstract] [Full Text] [PDF]

				G. Wlasiuk, S. Khan, W. M. Switzer, and M. W. Nachman A History of Recurrent Positive Selection at the Toll-Like Receptor 5 in Primates Mol. Biol. Evol., April 1, 2009; 26(4): 937 - 949. [Abstract] [Full Text] [PDF]

				S. S. Yoon and J. J. Mekalanos Decreased Potency of the Vibrio cholerae Sheathed Flagellum To Trigger Host Innate Immunity Infect. Immun., March 1, 2008; 76(3): 1282 - 1288. [Abstract] [Full Text] [PDF]

				T. R. Ziegler, M. Luo, C. F. Estivariz, D. A. Moore III, S. V. Sitaraman, L. Hao, N. Bazargan, J.-M. Klapproth, J. Tian, J. R. Galloway, et al. Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R402 - R410. [Abstract] [Full Text] [PDF]

				I. Nadal, E. Donant, C. Ribes-Koninckx, M. Calabuig, and Y. Sanz Imbalance in the composition of the duodenal microbiota of children with coeliac disease J. Med. Microbiol., December 1, 2007; 56(12): 1669 - 1674. [Abstract] [Full Text] [PDF]

				A. T. Gewirtz TLRs in the Gut. III. Immune responses to flagellin in Crohn's disease: good, bad, or irrelevant? Am J Physiol Gastrointest Liver Physiol, March 1, 2007; 292(3): G706 - G710. [Abstract] [Full Text] [PDF]

				C. J. Sanders, Y. Yu, D. A. Moore III, I. R. Williams, and A. T. Gewirtz Humoral immune response to flagellin requires T cells and activation of innate immunity. J. Immunol., September 1, 2006; 177(5): 2810 - 2818. [Abstract] [Full Text] [PDF]